Last reviewed · How we verify
NCT05858385
Predictive Study on Acute Radiation Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients
trial testing Intervention based on key factors identified by the severe RIOM prediction model in Nasopharyngeal Carcinoma by AJCC V8 Stage in 700 participants. Currently enrolling.
30 June 2024
Quick facts
| Lead sponsor | Affiliated Cancer Hospital & Institute of Guangzhou Medical University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 700 |
| Start date | 22 September 2022 |
| Primary completion | 30 June 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Intervention based on key factors identified by the severe RIOM prediction model
Conditions studied
- Nasopharyngeal Carcinoma by AJCC V8 Stage — all drugs for Nasopharyngeal Carcinoma by AJCC V8 Stage →
- Radiation Induced Mucositis — all drugs for Radiation Induced Mucositis →
Sponsor
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Who can join
Adults 18 to 75, any sex, with Nasopharyngeal Carcinoma by AJCC V8 Stage or Radiation Induced Mucositis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Exploring effective risk prediction models for severe Radiation-Induced Oral Mucositis (RIOM/RTOM), providing a research basis for mitigating oral radiation toxicity, and effectively improving the sensitivity of dentists in predicting the risk of severe RIOM in locally advanced nasopharyngeal carcinoma patients.Based on precise radiotherapy, it is proposed to extract OAR using the contour of local oral areas. Explore more accurate RIOM dose-response relationships.Exploring a new type of fusion classifier, by complementing the information between each base classifier, helps to maximize the utilization of the information contained in different factors to build a more objective, reliable, and efficient multi criteria decision-making based risk prediction model for severe RIOM. It use predictive models to identify key risk factors for severe RIOM and further validate the effectiveness of this risk factor in reducing the risk of severe RIOM on risk factors for severe RIOM identified by the predictive mode.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Control of dental calculus Prevents severe Radiation-Induced oral mucositis in patients undergoing radiotherapy for nasopharyngeal carcinoma.
Zeng Y, Hu Y, Wang L, Liao Z, et al · · 2025 · cited 2× · PMID 40157544 · DOI 10.1016/j.radonc.2025.110872
Verify or expand the search:
- PubMed search for NCT05858385
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Nasopharyngeal Carcinoma by AJCC V8 Stage
Currently open trials in the same condition.
- NCT06095154 — CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma · Phase 3 · recruiting
- NCT06509009 — Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma · Phase 2 · recruiting
- NCT05513573 — Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplul · Phase 2 · active not recruiting
- NCT05717790 — Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma · NA · recruiting
Other Affiliated Cancer Hospital & Institute of Guangzhou Medical University trials
Trials by the same sponsor.
- NCT07286240 — QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer · Phase 2 · recruiting
- NCT07286253 — QL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Phase II Trial · Phase 2 · recruiting
- NCT06594172 — Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy · Phase 2 · not yet recruiting
- NCT06570538 — Analgesic Efficacy of an Opioid-free Postoperative Pain Management Strategy Versus a Conventional Opioid-based Strategy · EARLY_PHASE1 · not yet recruiting
- NCT06327932 — HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05858385 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Affiliated Cancer Hospital & Institute of Guangzhou Medical University
- Last refreshed: 30 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05858385.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing